| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 31st December 2020 | Gary Sender | 32 | Payment by withholding | $2.42 | $77.44 |
| 17th December 2020 | Charles A Jr Rowland | 10,909 | Open or private sale | $117.82 | $1,285,298.38 |
| 17th December 2020 | Charles A Jr Rowland | 10,909 | Exercise of derivative | $19.53 | $213,052.77 |
| 7th December 2020 | Carrie L. Bourdow | 132,934 | Payment by withholding | $2.27 | $301,760.18 |
| 30th November 2020 | Robert Crotty | 368 | Payment by withholding | $0.43 | $157.14 |
| 30th November 2020 | Steven P. Gelone | 628 | Payment by withholding | $0.43 | $268.16 |
| 30th November 2020 | Jennifer Schranz | 301 | Payment by withholding | $0.43 | $128.53 |
| 30th November 2020 | Theodore R Schroeder | 1,211 | Payment by withholding | $0.43 | $517.10 |
| 30th November 2020 | Gary Sender | 312 | Payment by withholding | $0.43 | $133.22 |
| 3rd November 2020 | Charles A Jr Rowland | 694 | Open or private sale | $95.97 | $66,603.18 |
Nabriva Therapeutics Plc
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company. It engages in the research and development of novel antibiotics to treat serious infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Ticker: NBRV
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1641640
Employees: 162
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $50 M (-42%)
Inventory, Net: $5 M (661%)
Assets, Current: $62 M (-31%)
Property, Plant and Equipment, Net: $2 M (-12%)
Assets: $65 M (-30%)
Accounts Payable, Current: $3 M (-43%)
Accrued Liabilities, Current: $8 M (0%)
Liabilities, Current: $11 M (-33%)
Long-term Debt, Excluding Current Maturities: $7 M (-78%)
Other Liabilities, Noncurrent: $2 M (24%)
Liabilities: $21 M (-61%)
Common Stock, Value, Issued: $1 M (51%)
Common Stock, Shares, Issued: $143 M (51%)
Additional Paid in Capital, Common Stock: $558 M (8%)
Retained Earnings (Accumulated Deficit): $515 M (8%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $27 Th (0%)
Stockholders' Equity (Parent): $44 M (0%)
Liabilities and Equity: $65 M (-30%)
Revenue: $487 Th (0%)
Cost of Revenue: $368 Th (-2%)
Research and Development: $6 M (-43%)
Operating Income/Loss: $14 M (-58%)
Provision for income taxes: $119 Th (19%)
News
Nabriva Therapeutics (NBRV) Investor Presentation - Slideshow
16th January 2021
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering
11th December 2020
Nabriva Therapeutics Announces Proposed Public Offering
10th December 2020
Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split
2nd December 2020